

SHORT REPORT

Open Access



# Enhanced mammalian genome editing by new Cas12a orthologs with optimized crRNA scaffolds

Fei Teng<sup>1,2,3†</sup>, Jing Li<sup>1,2,4†</sup>, Tongtong Cui<sup>1,2,3†</sup>, Kai Xu<sup>1,2,3</sup>, Lu Guo<sup>1,2,3</sup>, Qingqin Gao<sup>1,2,3</sup>, Guihai Feng<sup>1,2</sup>, Chuanyuan Chen<sup>3,5</sup>, Dali Han<sup>3,5</sup>, Qi Zhou<sup>1,2,3\*</sup> and Wei Li<sup>1,2,3\*</sup>

## Abstract

CRISPR-Cas12a/Cpf1, a single RNA-guided endonuclease system, provides a promising tool for genome engineering. However, only three Cas12a orthologs have been employed for mammalian genome editing, and the editing efficiency as well as targeting coverage still requires improvements. Here, we harness six novel Cas12a orthologs for genome editing in human and mouse cells, some of which utilize simple protospacer adjacent motifs (PAMs) that remarkably increase the targeting range in the genomes. Moreover, we identify optimized CRISPR RNA (crRNA) scaffolds that can increase the genome editing efficiency of Cas12a.

**Keywords:** CRISPR-Cas12a/Cpf1, crRNA, Genome editing, Human cells, Mouse cells

## Background

Clustered regularly interspaced short palindromic repeats (CRISPR)-Cas12a/Cpf1 is the type V A CRISPR-Cas (CRISPR-associated proteins) system that has been recently harnessed for genome editing [1]. Several unique features make Cas12a distinguished from Cas9, providing a substantial expansion of CRISPR-based genome-editing tools. First, Cas12a is a single crRNA-guided endonuclease [1], while Cas9 is guided by a dual-RNA system consisting of a crRNA and a trans-activating crRNA (tracrRNA) [2]. Second, Cas12a recognizes a 5' T-rich protospacer adjacent motif (PAM) [1], different from the 3' G-rich PAM utilized by Cas9 [3, 4]. Third, after cleavage of double-stranded DNAs (dsDNAs), Cas12a generates staggered ends distal to the PAM site [1], whereas Cas9 introduces blunt ends within the PAM-proximal target site [5]. Moreover, RuvC and Nuc domains of Cas12a are responsible for target DNA cleavage [6], whereas Cas9 uses the RuvC and HNH endonuclease domains to cleave the target DNAs [3]. While these diverse properties of the CRISPR-Cas12a system provide potential for the development of versatile tools for genome

engineering [1, 7–11], there are still challenges, including few currently identified orthologs, limited genomic targeting coverage, and relatively low editing efficiency [1, 12–15]. To address these limitations, we aimed to identify novel Cas12a nucleases with simpler PAM requirements which can increase its targeting range and engineer the crRNA scaffold to achieve higher efficiencies of genome editing.

## Results and discussion


To search for new Cas12a proteins for genome editing, we first used PSI-BLAST program [16] and identified 21 non-redundant CRISPR-Cas12a loci which have not previously been employed for genome editing and 4 Cas12a proteins (BoCas12a, BsCas12a, PbCas12a, and TsCas12a) recently being characterized during our paper submission [17] (Additional file 1: Supplementary Methods and Additional file 2: Figure S1a). The alignment of their mature crRNA sequences showed that they used 5 highly conserved crRNA scaffolds in total (scaffolds 1~5, loop region: UAUU, UGUU, UUUU, UAGU, and UGUGU, respectively) that only had sequence variations in the loop region (Fig. 1a and Additional file 2: Figure S1b), which is consistent with the previous report [1]. We synthesized 12 Cas12a genes coding for approximately 1200~1300 amino acids or less and 3 corresponding crRNA sequences (scaffolds 1, 2, and 5) (Additional file 1: Supplementary

\* Correspondence: [qzhou@ioz.ac.cn](mailto:qzhou@ioz.ac.cn); [liwei@ioz.ac.cn](mailto:liwei@ioz.ac.cn)

†Fei Teng, Jing Li and Tongtong Cui contributed equally to this work.

<sup>1</sup>State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China  
Full list of author information is available at the end of the article





**Fig. 1** New Cas12a orthologs harnessed to robustly edit mammalian genomes. **a** Alignment of direct repeats (DRs) from the 25 Cas12a family proteins. Note that 4 Cas12a bacterial loci contain no DR array. Non-conserved bases in the loop are colored, and the conserved stem duplex is highlighted in pink. **b** (Upper) schematic showing the sequence of crRNA targeting the human *CD34* gene site 1. (Lower) T7E1 analysis of targeted indel frequencies induced by the 6 Cas12a candidates (ArCas12a, BsCas12a, HkCas12a, LpCas12a, PrCas12a, and PxCas12a) as indicated. AsCas12a was used as positive control. GFP, an empty backbone vector without Cas12a protein expression. M, DNA marker. **c** (Upper) schematic showing the sequence of crRNA targeting the human *CD34* gene site 8. (Lower) T7E1 assay result indicated that HkCas12a facilitated targeted indels directed by 5'-TCTN PAM. GFP, an empty backbone vector without Cas12a protein expression. M, DNA marker

Methods, Additional file 2: Figure S1b, c, Additional file 3: Table S1, Additional file 4: Table S2, and Additional file 5: Supplementary Sequences). Then, we purified the Cas12a proteins expressed in *E. coli* cells (Additional file 2: Figure S2a) and incubated them with in vitro-transcribed crRNAs and dsDNA substrates for in vitro DNA cleavage assay (Additional file 2: Figure S2b and Additional file 4: Table S3). The conservation of the crRNA scaffolds suggested that these Cas12a proteins might also recognize the 5' T-rich PAM as the previous report indicated [1]. Indeed, we found that crRNA scaffold 1, 2, or 5 enables Cas12a proteins to cleave the target DNAs with a 5'-TTTN or even 5'-TTN PAM in vitro (Additional file 2: Figure S2c).

To further characterize the PAM requirements, we analyzed the Cas12a cleavage activity on dsDNA substrates bearing 5'-TTN, 5'-TNN, and 5'-NTN PAMs (Additional file 4: Table S3). We found that ArCas12a, BsCas12a, and PrCas12a recognized 5'-TTN PAM for dsDNA cleavage, and HkCas12a recognized a simple 5'-YYN PAM (Y:T or C) (Additional file 2: Figure S2d).


Next, we explored the capability of these Cas12a orthologs to cleave the target genomic sequences in mammalian cells. The 12 synthesized Cas12a genes fused with 2 nuclear localization signals (NLSs) at each end were constructed into mammalian expression vectors for Cas12a expression in human and mouse cells (Additional file 2: Figure S3a

and Additional file 5: Supplementary Sequences). After transfection, the immunofluorescence staining results showed clear nuclear compartmentalization of the Cas12a proteins in mammalian cells (Additional file 2: Figure S3a). Then, we co-transfected human embryonic kidney 293FT cells or mouse embryonic stem cells (ESCs) with individual Cas12a orthologs and crRNAs (scaffold 1) to target endogenous loci containing the 5' T-rich PAMs. Results of T7 endonuclease I (T7EI) assay showed that 6 Cas12a nucleases (ArCas12a, BsCas12a, HkCas12a, LpCas12a, PrCas12a, and PxCas12a) could all facilitate genome editing in both human and mouse genomes with the 5'-TTTN PAM (Fig. 1b and Additional file 2: Figure S3b) or 5'-TTN PAM (Additional file 2: Figure S3c). Sanger sequencing results further confirmed the capacity of these 6 Cas12a nucleases to introduce insertions or deletions (indels) at target sites in the mammalian genomes (Additional file 2: Figure S3d-f). We next focused on exploring the in vivo PAM requirement of HkCas12a, which owned the simplest PAM (5'-YYN) in vitro (Additional file 2: Figure S2d). By targeting the human *AAVS1*, *CD34*, and *RNF2* loci in 293FT cells (Additional file 4: Table S4), we showed that HkCas12a induced indels at target sites with the 5'-YTN and 5'-TYYN PAMs (Additional file 2: Figure S4a, b). Then, we compared the genomic coverage ability of HkCas12a with the previously reported AsCas12a [1], by targeting the endogenous loci containing requisite PAMs in mammalian genomes. Notably, HkCas12a possessed an expanded genomic coverage capacity than did AsCas12a (Fig. 1c and Additional file 2: Figure S4c). These data demonstrated that we harnessed new Cas12a nucleases for mammalian genome editing with their PAMs determined as 5'-TTN, 5'-YTN, or 5'-TYYN in vivo, which markedly increases the targeting range of Cas12a nucleases in mammalian genomes.

Interestingly, our in vitro DNA cleavage results showed that the crRNA scaffolds carrying nucleotide (nt) substitutions had variable effects on the cleavage activity of Cas12a nucleases (Additional file 2: Figure S2c), which is consistent with the previous report [1]. To test such effects in mammalian cells, three naturally existed crRNA scaffolds (scaffold 1, 2, or 5) and two artificial scaffolds (scaffold 6 or 7) were individually transfected into mouse ESCs with each of the six functional Cas12a nucleases to target the mouse *MeCP2* gene (Additional file 2: Figure S5a, Additional file 4: Table S5, and Additional file 5: Supplementary Sequences). Indel frequency analysis by T7EI assay showed that the highest cleavage efficiency was achieved by the Cas12a nuclease with its cognate crRNA scaffold in most cases (Additional file 2: Figure S5b), consistent with the previous report [13, 18]. Surprisingly, the Cas12a nuclease with artificial crRNA scaffolds could also induce high indel frequency at target sites, such as LpCas12a/crRNA 6 and PrCas12a/crRNA 7 (Additional file 2: Figure S5b),

suggesting the potential of increasing Cas12a cleavage efficiency by optimizing the loop sequences of crRNA scaffolds. To test this hypothesis, we synthesized 256 crRNA scaffolds bearing all the possible nucleotide substitutions at the 4-nt loop (Fig. 2a and Additional file 4: Table S5). Next, we used these crRNA variants with PrCas12a and BsCas12a, respectively, to target the mouse *Nrl* locus, and compared the targeting efficiencies of these crRNA variants with that of the crRNA scaffold 1. The results showed that the crRNA scaffold 4n96 (loop region: UAUG) exhibited an enhanced targeting efficiency compared with the original scaffold 1 when working together with both PrCas12a and BsCas12a (Additional file 2: Figure S6a, b). To confirm these findings, we used 10 crRNA scaffolds with nucleotide substitutions in a 3-nt loop, 25 crRNA scaffolds with nucleotide substitutions in a 5-nt loop, and 25 crRNA scaffolds with a 4-nt loop including the 4n96, to target another site within the mouse *MeCP2* gene locus (Additional file 4: Table S5). Consistent with the above results, the scaffold 4n96 was identified to exhibit a higher targeting efficiency compared with other crRNA scaffolds (Additional file 2: Figure S6c, d). Moreover, we further employed the GFP disruption assay to analyze the effect of crRNA scaffold 4n96 on the genome cleavage efficiency of Cas12a nucleases. The crRNA scaffolds 1 and 4n96 were transfected with PrCas12a and BsCas12a, respectively, to target the integrated GFP reporter. Compared with crRNA scaffold 1, the scaffold 4n96 substantially increased the Cas12a targeting efficiency at two sites of the GFP gene (Fig. 2b and Additional file 2: Figure S7a). Next, we tested the generality of this enhanced genomic cleavage activity mediated by scaffold 4n96 by examining more target sites and Cas12a nucleases. We targeted six independent sites from both human and mouse genomes by PrCas12a and BsCas12a individually. The results showed that compared with the crRNA scaffold 1, the scaffold 4n96 significantly increased the cleavage activity of both PrCas12a and BsCas12a at all these six sites (Fig. 2c and Additional file 2: Figure S7b). Moreover, the genome cleavage activity of the other three Cas12a nucleases (ArCas12a, HkCas12a, and PxCas12a) was increased using the crRNA scaffold 4n96 compared with using scaffold 1 (Additional file 2: Figure S7c). These results strongly suggested that the effect of enhanced Cas12a-mediated genome editing by the scaffold 4n96 was universal. Taken together, our results demonstrated that the crRNA scaffold 4n96 carrying nucleotide substitution at the loop region can markedly increase the Cas12a-mediated genome editing efficiencies.

We further characterized the targeting efficiency and specificity of these newly identified Cas12a nucleases. First, we directly compared the relative targeting activities of Cas12a and SpCas9, the efficiency of which is considered as the current gold standard for genome editing. By performing T7EI analyses of targeted indels



**Fig. 2** Enhanced targeted indel frequencies by optimized crRNA scaffold. **a** Schematic showing the workflow of crRNA scaffold optimization and screening. **b** Efficiencies of GFP disruption in human 293FT cells generated by PrCas12a/scaffold 1 and PrCas12a/scaffold 4n96, respectively. Error bars indicate standard errors of the mean (SEM),  $n = 3$ . \* $p$  value < 0.05 and \*\* $p$  value < 0.01. **c** PrCas12a-induced targeted indel frequencies at six different endogenous gene target sites with scaffold 1 and scaffold 4n96. Error bars indicate SEM,  $n = 3$ . \* $p$  value < 0.05 and \*\* $p$  value < 0.01

of endogenous genomic sites, we found that the average targeting efficiencies of these Cas12a proteins (ArCas12a, BsCas12a, HkCas12a, and PrCas12a) are lower than SpCas9, although these Cas12a proteins could achieve higher targeting efficiencies when directed by crRNA 4n96 than crRNA 1 (Additional file 4: Table S7). Meanwhile, to address the off-targeting risks of Cas12a, we performed off-target predictions using Cas-OFFinder [19] followed by targeted deep sequencing. The results showed that both Cas12a (BsCas12a and PrCas12a) and SpCas9 exhibited a low incidence of off-target mutations at the endogenous *DNMT1* site 1 in targeted human 293FT cells (Additional file 4: Table S8). Moreover, the genome-wide off-target analysis by whole genome sequencing (WGS) also showed a low incidence of off-target mutations for both Cas12a and SpCas9 (Additional file 4: Table S9). All these data indicated the minimal off-target risks of Cas12a, which is consistent with previous reports [13, 14].

In this work, we report the identification of six new Cas12a nucleases for genome editing in mammalian cells, including one Cas12a ortholog (HkCas12a) recognizing more flexible 5'-YTN and 5'-TYYN PAMs that can provide broader genome coverage. However, the precise PAM sequences of these orthologs still need to

be determined in the future using high-throughput approaches. The non-canonical PAM recognition by HkCas12a was possibly due to the variation of L642 residue, which was equivalent to K592 of LbCas12a and was responsible for the non-canonical PAM recognition (Additional file 2: Figure S8) [20, 21]. As previous studies indicated, crRNA scaffolds could affect or even enhance the targeting activities of CRISPR-Cas systems [1, 12, 13, 18]. Through engineering the nucleotide substitutions at the loop region, we identify a crRNA scaffold that markedly improves the Cas12a-mediated genome editing efficiency. The crystal structures of Cas12a-RNA-DNA complex have shown that the nucleotides in the loop region of crRNA scaffold interact with Cas12a residues [6, 22], indicating nucleotide substitutions in the loop region of crRNA scaffold would affect the activities of Cas12a-crRNA complex [18]. Further structural characterization of Cas12a-crRNA-DNA complexes with different crRNA scaffolds will help the elucidation of the exact mechanisms of this improvement in the future. Collectively, our findings expand the CRISPR-Cas12a genome editing toolbox and may enhance their application in mammalian genome engineering and human gene therapy.

## Methods

### Identify new CRISPR-Cas12a loci

PSI-BLAST program [16] was applied to identify Cas12a homologs in the NCBI non-redundant protein sequence database using AsCas12a and LbCas12a protein sequences [1]. Cas12a loci not yet harnessed for mammalian genome editing were chosen as candidates for analysis. CRISPR repeats were identified using CRISPR-Finder [23].

### crRNA scaffold library construction

Paired degenerate primers were synthesized and annealed to form a duplex with 5' overhangs (Additional file 4: Table S5). Then, they were constructed into an U6 promoter-driven expression vector (Additional file 5: Supplementary Sequences). The scaffold variants were randomly picked out from cultured plates and then sequenced.

### Cell culture, transfection, and fluorescence-activated cell sorting

Human embryonic kidney cell line 293FT and human cervical cancer cell line HeLa were cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco) supplemented with 10% fetal bovine serum (FBS, Gibco) and 1% Antibiotic-Antimycotic (Gibco). Mouse embryonic stem (mES) cell line was maintained in N2B27 medium plus 2i (Stemgent) and mLIF (Millipore). The N2B27 medium consists of DMEM/F12 (Gibco) and Neurobasal (Gibco) at a ratio of 1:1 and was supplemented with 1% N-2 supplement (Gibco), 0.5% B-27 supplement (Gibco), 20 ng/ml BSA (Sigma), 10 µg/ml insulin (Roche), 1% GlutaMAX (Gibco), 5% knockout serum replacement (KOSR, Gibco), 0.1% β-mercaptoethanol (Gibco), and 1% Antibiotic-Antimycotic (Gibco). 293FT cells were transfected using Lipofectamine LTX (Invitrogen) following the manufacturer's recommended protocol. mES cells were transfected via electroporation using Neon™ transfection system (Invitrogen) following the manufacturer's recommended protocol. For each well of a 24-well plate, a total of 750 ng plasmids (Cas12a-2AeGFP: crRNA = 2: 1) was used. Then, 48 h following transfection, GFP-positive cells were sorted using the MoFlo XDP (Beckman Coulter).

### T7 endonuclease I assay for genome modification

Cells were collected after 48 h post-transfection for genomic DNA extraction. GFP-positive cells sorted by FACS were lysed directly using Buffer L (Bimake). The genomic region flanking the Cas12a targeting site of each gene was PCR-amplified (Additional file 4: Table S6), and products were purified using DNA Clean & Concentrator (ZYMO Research) following the manufacturer's protocol. A total of ~200 ng purified PCR amplicons

was mixed with 1 µl NEBuffer 2 (NEB) and diluted in ddH<sub>2</sub>O to 10 µl, then subjected to a re-annealing process to form a heteroduplex according to our previously reported procedure [24]. After re-annealing, the products were treated with T7EI (NEB) following recommending protocol, and 2.5% agarose gels (Takara) were used for further analysis. Indels were calculated via band intensities based on previously reported method [25].

### GFP disruption assay

Human 293FT.eGFP cells harboring a single-copy, integrated AAVS1-eGFP gene were generated by our lab. These cells were transfected with Cas12a expression plasmid and crRNA expression plasmid, or Cas12a expression plasmid and an U6 promoter-driven empty plasmid as a negative control using Lipofectamine LTX (Invitrogen). Three days post-transfection, cells were analyzed on the MoFlo XDP (Beckman Coulter). For each sample, transfections and flow cytometry measurements were performed in triplicate.

## Additional files

**Additional file 1:** Supplementary methods. (PDF 124 kb)

**Additional file 2: Figure S1.** Phylogeny tree of non-redundant Cas12a orthologs and selected Cas12a loci for genome editing. **Figure S2.** In vitro DNA cleavage assay for Cas12a PAM sequences. **Figure S3.** Six new Cas12a proteins mediated robust genome editing in mammalian cells. **Figure S4.** Increased genome-wide coverage of HkCas12a with altered PAMs. **Figure S5.** crRNA scaffold alters targeted indel efficiencies of Cas12a proteins. **Figure S6.** crRNA scaffold optimization and screening. **Figure S7.** Enhanced targeted efficiency with optimized crRNA scaffold. **Figure S8.** Conserved residues in PAM-interacting (PI) domain of Cas12a proteins. (PDF 18496 kb)

**Additional file 3: Table S1.** Oligonucleotides (oligos) for Cas12a gene synthesis. (XLSX 81 kb)

**Additional file 4: Table S2.** Sequences of targeting crRNAs used for in vitro RNA transcription. **Table S3.** Target sequences harboring various 5' PAM sequences used for in vitro DNA cleavage assay. **Table S4.** Protospacer sequences used for genome editing. **Table S5.** crRNA scaffold optimization and screening. **Table S6.** Primer sequences used for PCR amplification. **Table S7.** Frequency of Cas12a- and SpCas9-mediated targeted indel mutations at on-target sites in human 293FT cells. **Table S8.** Off-target analysis by targeted deep sequencing in the human 293FT cells. **Table S9.** Off-target analysis by whole genome sequencing (WGS) in human 293FT cells. (PDF 395 kb)

**Additional file 5:** Supplementary Sequences. The humanized Cas12a coding sequences, protein sequences, U6-crRNA backbone sequences, mammalian and prokaryotic expression vector sequences used in this study. (PDF 183 kb)

### Abbreviations

Cas: CRISPR-associated protein; CRISPR: Clustered regularly interspaced short palindromic repeats; crRNA: CRISPR RNA; dsDNA: Double-stranded DNA; indel: Insertion or deletion; NLS: Nuclear localization signal; nt: Nucleotide; PAM: Protospacer adjacent motif; T7EI: T7 endonuclease I; tracrRNA: Transactivating crRNA

### Acknowledgements

We thank Shi-Wen Li, Xi-Li Zhu, Qing Meng and Xia Yang for their help with fluorescence-activated cell sorting.

**Funding**

This study was supported by the Strategic Priority Research Program of the Chinese Academy of Sciences (Grant No. XDA16030400), the National Natural Science Foundation of China (Grant No. 31621004, 31422038), the National Key Research and Development Program (Grant No. 2017YFA0103803), the National Basic Research Program of China (Grant No. 2014CB964800), CAS Key Projects (Grant No. QYZDY-SSW-SMC022, QYZDB-SSW-SMC002).

**Availability of data and materials**

The datasets supporting the conclusions of this article are included within the article and its additional files. The raw sequence data reported in this paper have been submitted to the NCBI BioSample (<https://www.ncbi.nlm.nih.gov/biosample>) under accession number PRJNA511656 [26].

**Authors' contributions**

WL and QZ conceived this project, supervised the experiments, and wrote the paper. FT performed the experiments, analyzed the data, and wrote the paper. JL and TC performed the experiments and analyzed the data. KX, LG, QG, and GF performed the experiments. CC and DH analyzed the data. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

A patent application has been filed relating to this work. The authors declare that they have no competing interests, and they plan to deposit the reagents in Addgene to freely share with the academic community.

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

<sup>1</sup>State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China. <sup>2</sup>Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing 100101, China. <sup>3</sup>University of Chinese Academy of Sciences, Beijing 100049, China. <sup>4</sup>School of Life Sciences, University of Science and Technology of China, Hefei 230026, China. <sup>5</sup>Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100101, China.

Received: 2 July 2018 Accepted: 3 January 2019

Published online: 05 February 2019

**References**

- Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM, Makarova KS, Essletzbichler P, Volz SE, Joung J, van der Oost J, Regev A, et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. *Cell*. 2015; 163:759–71.
- Deltcheva E, Chylinski K, Sharma CM, Gonzales K, Chao Y, Pirzada ZA, Eckert MR, Vogel J, Charpentier E. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. *Nature*. 2011;471:602–7.
- Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science*. 2012;337:816–21.
- Fonfara I, Le Rhun A, Chylinski K, Makarova KS, Leclercq AL, Bzdrenga J, Koonin EV, Charpentier E. Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems. *Nucleic Acids Res*. 2014;42:2577–90.
- Garneau JE, Dupuis ME, Villion M, Romero DA, Barrangou R, Boyaval P, Fremaux C, Horvath P, Magadan AH, Moineau S. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. *Nature*. 2010;468: 67–71.
- Yamano T, Nishimasu H, Zetsche B, Hirano H, Slaymaker IM, Li Y, Fedorova I, Nakane T, Makarova KS, Koonin EV, et al. Crystal structure of Cpf1 in complex with guide RNA and target DNA. *Cell*. 2016;165:949–62.
- Kim Y, Cheong SA, Lee JG, Lee SW, Lee MS, Baek IJ, Sung YH. Generation of knockout mice by Cpf1-mediated gene targeting. *Nat Biotechnol*. 2016;34: 808–10.
- Hur JK, Kim K, Been KW, Baek G, Ye S, Hur JW, Ryu SM, Lee YS, Kim JS. Targeted mutagenesis in mice by electroporation of Cpf1 ribonucleoproteins. *Nat Biotechnol*. 2016;34:807–8.
- Zetsche B, Heidenreich M, Mohanraju P, Fedorova I, Neppers J, DeGennaro EM, Winblad N, Choudhury SR, Abudayyeh OO, Gootenberg JS, et al. Multiplex gene editing by CRISPR-Cpf1 using a single crRNA array. *Nat Biotechnol*. 2017;35:31–4.
- Tak YE, Kleinstiver BP, Nuñez JK, Hsu JY, Horng JE, Gong J, Weissman JS, Joung JK. Inducible and multiplex gene regulation using CRISPR-Cpf1-based transcription factors. *Nat Methods*. 2017;14:1163–6.
- Li X, Wang Y, Liu Y, Yang B, Wang X, Wei J, Lu Z, Zhang Y, Wu J, Huang X, et al. Base editing with a Cpf1-cytidine deaminase fusion. *Nat Biotechnol*. 2018;36:324–7.
- Tu M, Lin L, Cheng Y, He X, Sun H, Xie H, Fu J, Liu C, Li J, Chen D, et al. A 'new lease of life': FnCpf1 possesses DNA cleavage activity for genome editing in human cells. *Nucleic Acids Res*. 2017;45:11295–304.
- Kim D, Kim J, Hur JK, Been KW, Yoon SH, Kim JS. Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells. *Nat Biotechnol*. 2016;34:863–8.
- Kleinstiver BP, Tsai SQ, Prew MS, Nguyen NT, Welch MM, Lopez JM, McCaw ZR, Aryee MJ, Joung JK. Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells. *Nat Biotechnol*. 2016;34:869–74.
- Kim HK, Song M, Lee J, Menon AV, Jung S, Kang YM, Choi JW, Woo E, Koh HC, Nam JW, Kim H. In vivo high-throughput profiling of CRISPR-Cpf1 activity. *Nat Methods*. 2017;14:153–9.
- Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res*. 1997;25:3389–402.
- Zetsche B, Strecker J, Abudayyeh OO, Gootenberg JS, Scott DA, Zhang F. A survey of genome editing activity for 16 Cpf1 orthologs. *bioRxiv*. 2017. <https://doi.org/10.1101/134015>.
- Li B, Zhao W, Luo X, Zhang X, Li C, Zeng C, Dong Y. Engineering CRISPR-Cpf1 crRNAs and mRNAs to maximize genome editing efficiency. *Nat Biomed Eng*. 2017;1:0066.
- Bae S, Park J, Kim JS. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. *Bioinformatics*. 2014;30:1473–5.
- Nishimasu H, Yamano T, Gao L, Zhang F, Ishitani R, Nureki O. Structural basis for the altered PAM recognition by engineered CRISPR-Cpf1. *Mol Cell*. 2017; 67:139–47 e132.
- Yamano T, Zetsche B, Ishitani R, Zhang F, Nishimasu H, Nureki O. Structural basis for the canonical and non-canonical PAM recognition by CRISPR-Cpf1. *Mol Cell*. 2017;67:633–45 e633.
- Gao P, Yang H, Rajashankar KR, Huang Z, Patel DJ. Type V CRISPR-Cas Cpf1 endonuclease employs a unique mechanism for crRNA-mediated target DNA recognition. *Cell Res*. 2016;26:901–13.
- Grissa I, Vergnaud G, Pourcel C. CRISPRFinder: a web tool to identify clustered regularly interspaced short palindromic repeats. *Nucleic Acids Res*. 2007;35:W52–7.
- Li W, Teng F, Li T, Zhou Q. Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems. *Nat Biotechnol*. 2013;31:684–6.
- Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F. Multiplex genome engineering using CRISPR/Cas systems. *Science*. 2013;339:819–23.
- Teng F, Li J, Cui T, Xu K, Guo L, Gao Q, Feng G, Chen C, Han D, Zhou Q, Li W. Enhanced mammalian genome editing by new Cas12a orthologs with optimized crRNA scaffolds. *BioSample*. <https://www.ncbi.nlm.nih.gov/bioproject/PRJNA511656/>.